NK cells represent a very promising source for adoptive cellular approaches for cancer immunotherapy, and extensive research has been conducted, including clinical trials. Gene modification of NK cells can direct their specificity and enhance their function, but the efficiency of gene transfer techniques is very limited. Here we describe two protocols designed to generate mature human NK cells from gene-modified hematopoietic stem cells. These protocols use chimeric antigen receptor as the transgene, but could potentially be modified for the expression any particular transgene in human NK cells.
Introduction
Natural Killer (NK) cells are innate immune cells that mediate spontaneous cytotoxicity against tumor and virus-infected cells, and many clinical trials have attempted to harness their properties for cellular therapies (1-6). Gene transfer technology can enhance the efficacy of such efforts by improving NK cell survival or function, or engineering antigen specificity (7-9).
Chimeric antigen receptors (CAR) are engineered fusion proteins that combine the antigen specificity of antigen-binding moieties of monoclonal antibodies and intracellular activation motifs capable to activate immune cells. Preliminary evidence suggests that NK cells with specificity directed by chimeric antigen receptors may have enhanced cytotoxicity (10-12).
Generation of mature NK cells from hematopoietic stem cells provides the opportunity of generation of younger NK cells and expansion of specific gene-modified clones starting from a smaller number of previously isolated and cryopreserved initial cells, with the added advantage of generation of multiple batches from the same donor (13-16). In this chapter we describe a protocol for NK cell differentiation from human hematopoietic stem cells (HSC) modified to express chimeric antigen receptors using co-culture with a feeder stroma of murine OP9-DL1 cells in presence of human recombinant cytokines (15). Alternatively, we describe a feeder-free protocol for generation of gene-modified NK cells from human hematopoietic stem cells using insulin-like growth factor 1 (IGF-1) (17). The transgene used in this protocol is a CD19-specific CAR, but the HSC could potentially receive any type of persistent gene modification for expression in differentiated NK cells. 6 2. Falcon 48, 12 and 6 well tissue culture-treated microplates, sterile.
Methods

Isolation and cryopreservation of umbilical cord blood HSC (see Note 1)
Isolation of CD34-positive cells from umbilical cord blood collected within 48 hours will increase cell recovery. The cord blood unit can be kept at room temperature until isolation procedure. The isolation procedure should be conducted in a biosafety cabinet to ensure sterility and personal protection.
1. Dilute umbilical cord blood with equal volume of PBS.
2. Pipette 15 mL of Ficoll into a 50 mL conical tube.
3. Layer 35 mL of cord blood onto Ficoll.
4. Centrifuge at 400 g for 30 minutes at 20 o C without brake.
Prepare isolation buffer by diluting MACS BSA Stock Solution into autoMACS Rinsing
Solution according to the manufacturer's instructions, and keep it ice-cold.
6. Collect the buffy coat of all post-centrifugation Ficoll tubes with a sterile Pasteur pipette or a serological pipette into a new 50 mL conical tube.
7. Dilute such collected buffy coat with equal volume of PBS.
8. Centrifuge at 300 g for 15 minutes at 4 o C, with brake on.
9. Remove supernatant.
10. Collect all cell pellets into one 50 mL conical tube, and complete to 50 mL with ice-cold isolation buffer.
11. Count cells.
12. Centrifuge at 250 g for 5 minutes at 4 o C, with brake on. 
Lentiviral transduction of HSC
Before a NK differentiation protocol is initiated, the investigators should evaluate in preliminary experiments the optimal transduction conditions using the available preparations of lentiviral vectors in human HSC (18) (see Note 4). Gene-modified HSC should be placed in NK 8 differentiation culture conditions immediately after lentiviral transduction, and full expression of integrated vector copies will take place around ten days after transduction. We routinely use overnight cytokine pre-stimulation of HSC in plates coated with fibronectin fragment CH-296
RetroNectin before treatment with the lentiviral vector (15, 18). 
RetroNectin coating of transduction
Resuspend human CD34-positive cells at 1x10
6 cells/mL in transduction medium.
3. Plate 400 μL/well in the RetroNectin coated 48 well transduction plate (from step 1).
4. Incubate the plate for 14h in 5% CO2 at 37 o C for pre-stimulation; the cells will attach to the bottom coated with RetroNectin.
5. After pre-stimulation, add the necessary volume of lentiviral vector to ensure transduction efficiency at a viral vector copy number of 1-3 copies/cell (15, 18) as determined in preliminary experiments using available vector preparations (see Note 4).
6. Incubate transduction plate with added lentiviral vectors for 24h in 5% CO2 at 37 o C before transferring HSC to differentiation cultures.
Culture and passaging of OP9-DL1 stromal cells:
It is fundamental to keep healthy, low-passage, stromal cells for co-culture with the primary human cells (see Notes 3 and 6). All co-cultures should be performed using freshly prepared NK differentiation medium from the first day.
1. Vigorously pipette the HSC in the transduction plate after adding 0.5-1mL of NK differentiation medium per well, in order to detach all cells adherent to the bottom. 5. Gently add freshly prepared NK differentiation medium by slow pipetting against the wall for a total volume of 2 mL per well.
6. Split HSC every 3-4 days; vigorously pipette using P-1000 to resuspend cells and detach stroma; remove stromal cells using a 70µm cell strainer unto a 50mL conical tube, then repeat steps 2-5 in this section (see Note 10).
Maintain co-culture of transduced HSC with stromal cells for 35-40 days to obtain
functional NK cells (see Notes 11 and 12) (Fig. 2a) . CD56+ NK cells can be sorted via fluorescence activated cell sorting (FACS) or immunomagnetic bead selection for continued culture or functional assays such as cytotoxicity assessment.
Feeder-free differentiation culture (alternate protocol):
All media changes and splits should be performed using AIM V CC from the first day (see
Note 13).
1. Vigorously pipette the HSC in the transduction plate after adding 0.5-1mL of AIM V CC per well, in order to detach all cells adherent to the bottom.
2. Transfer cells to an appropriately sized conical tube. Centrifuge at 300g for 10 minutes.
Remove supernatant and resuspend cell pellet by flicking the tube (see Note 14). Add 1 mL (or appropriate volume) of AIM V CC.
3. Count cells using a viability dye (e.g., trypan blue) and adjust viable cell concentration to 0.5x10 6 cells/mL in AIM V CC. 8. CD56+ NK cells will begin to appear around Day 14, peak around Day 28 and begin to decline thereafter (Fig. 2b) . 4. In clinically-relevant experiments, the viral vector copy number per cell in HSC should be kept within 1-3 copies/cell, in order to avoid genotoxicity.
5.
A plate coated with RetroNectin can be preserved at 4oC for up to 7 days with every well filled with 1mL of wash buffer.
6. In the co-culture protocol have used non-irradiated OP9-DL1 stromal cells.
7. Start OP9-DL1 stromal cell culture 1-2 weeks before HSC transduction, in order to have at least a full T-75 flask with confluent stroma before starting the protocol. 12. The use of a NK cell expansion protocol will increase the final yield of the cell generation when used in sequence to the protocols described in this chapter. Cells should be transferred to the expansion protocol at day 30 or later, when cells have higher expression of CD16 and other mature NK cell-specific markers.
13. In preparation of AIM V CC, human AB serum must be heat inactivated at 56°C
for 30 min and sterile filtered to remove excess lipids. Alternatively, the AIM V Complete medium can be sterile filtered prior to the addition of cytokines. 14 14. In order to resuspend the cell pellet, it is important to flick the tube to disperse the cells rather than to directly pipet the pellet, which can cause shearing and decrease viability of cells at this point. B.
